Further studies of the details of other components that affect p27 function, e.g. CDKN1B mutations, alternative splicing and crosstalk with other cytoplasmic p27 interactions will contribute to a better understanding of the complex nature of p27 biological activity and inform the strategic design of new therapies for osteosarcoma patients. Here, CDKN1B is linked to osteosarcoma.